Perrigo Co Plc Stock Price, News & Analysis

Perrigo Company plc (NYSE: PRGO) announced plans to release its first quarter 2023 financial results on May 9, 2023, accompanied by a conference call at 8:30 A.M. (EST). The conference call will be accessible via live webcast on Perrigo's investor relations website. A taped replay will be available from 12:00 P.M. (EST) on May 9 until midnight on May 16, 2023.

Perrigo focuses on Consumer Self-Care Products and over-the-counter health solutions, aiming to empower consumers in managing their health independently. The company warns that the earnings report may include forward-looking statements, which are subject to various risks and uncertainties.

Perrigo Company plc (NYSE: PRGO) announced a rescheduled FDA meeting set for May 9-10, 2023, to review their application for the Opill^® daily oral contraceptive for over-the-counter (OTC) availability. If approved, Opill^® would be the first OTC daily birth control pill in the U.S. This initiative is supported by key medical organizations advocating for increased access to contraception. The establishment of a dedicated Women's Health strategic organization reflects Perrigo's commitment to addressing women's health needs, aiming to empower individuals with affordable contraceptive options.

Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Murray S. Kessler, along with CFO Eduardo Bezerra, will present at the 12th Annual UBS Global Consumer and Retail Conference on March 15, 2023, at 3:00 PM EST in New York City. The presentation aims to discuss their consumer self-care products and OTC health solutions.

Interested parties can access the live presentation via the Perrigo website at http://perrigo.investorroom.com/events-webcasts. For more information on the company, visit www.perrigo.com.

Perrigo Company plc (NYSE: PRGO) announced FDA approval for its Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, an over-the-counter equivalent to Advil Dual Action Tablets. This approval, received on the first day after Advil's marketing exclusivity expiration, showcases Perrigo's regulatory competency. The company plans to launch the product in Spring 2023. Retail sales for the national brand reached approximately $69 million in the past year. This dual-action formulation is designed to relieve various pain symptoms, reinforcing Perrigo's position in the consumer health market.

Perrigo Company plc (NYSE: PRGO) announced its Optimize and Accelerate strategic plan during its Virtual Investor Day, aiming for long-term profitable growth through 2025. The leadership team, including CEO Murray S. Kessler, highlighted initiatives to enhance commercial operations and drive organic growth of at least 3%. Key goals include achieving an adjusted gross margin of at least 40% and reducing net leverage to less than 3x adjusted EBITDA. Financial guidance for 2023 includes a reported net sales growth of 7% to 11% and adjusted diluted EPS between $2.50 and $2.70. The strategy emphasizes innovation, portfolio optimization, and strong cash generation to enhance shareholder value.